JBIO Jade Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why JBIO matters now
Jade Biosciences, Inc. (JBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $20.95 with -6.81% on the session and $683.5M in market capitalization; recent performance reads 1-month -23.13% and YTD +9.01%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-40.4M, and EPS of $-0.70. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -21.2%.
The latest indexable market news headline is "Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Fairmount Funds Management LLC filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.28
P/S
0.00
EV/EBITDA
-3.82
DCF Value
$2.74
FCF Yield
-21.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.3%
ROA
-40.6%
ROIC
-45.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-40.4M | $-0.70 |
| Q4 2025 | $0.00 | $-31.9M | $-0.65 |
| FY 2025 | $0.00 | $-127.4M | $-4.06 |
| Q3 2025 | $0.00 | $-25.2M | $-0.64 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$44.33
Target (Median)
$45.00
Target Range
$34.00 - $55.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.45
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.